





Next Generation RNA Medicines



December 2023

Forward Looking Statements

This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about: our strategy, future operations, collaborations, the likelihood of success (including safety and efficacy) and promise of our pipeline, the timing for selection of lead candidates, the development, manufacture or commercialization of our pipeline and partnered pipeline assets, the likelihood of success of, and achievement of revenues from, our partnered programs, the planned initiation, design or completion of clinical trials, the likelihood that we will obtain clearance from regulatory authorities to proceed with planned clinical trials, the ability to enroll subjects in clinical trials, the timing for receipt of data, the likelihood that preclinical or clinical data will be predictive of future clinical results, the likelihood that clinical data will be sufficient for regulatory approval or completed in time to submit an application for regulatory approval within a particular timeframe, the anticipated timing for regulatory submissions, the timing of, and expectations for, any results of any preclinical or clinical studies or regulatory approvals, the potential administration regimen or dosage, or ability to administer multiple doses of, any of our drug candidates, our manufacturing methods and technologies (including purification, lyophilization and stability of our products), the likelihood that a patent will issue from any patent application, our current cash position and adequacy of our capital to support future operations, and any statements other than statements of historical fact.


In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions (including the negative thereof) intended to identify forward looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing, and you should not place undue reliance on such forward-looking statements. The forward-looking statements contained or implied in this presentation are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Arcturus’ most recent Annual Report on Form 10-K with the SEC and in other filings that Arcturus makes with the SEC. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Trademark Attribution:

The Arcturus logo and other trademarks of Arcturus appearing in this presentation are the property of Arcturus. All other trademarks, services marks, and trade names in this presentation are the property of their respective owners.



Arcturus Therapeutics



Global Late-Stage Clinical
mRNA Medicines Company



Nasdaq: ARCT

Headquarters: San Diego, CA

Founded: 2013



mRNA Medicine Candidates

LUNAR-OTC *Ornithine Transcarbamylase Deficiency*

LUNAR-CF *Cystic Fibrosis*

Additional Earlier Stage Programs

Multiple Strategic Partners



Proprietary mRNA Technologies Driving Therapeutic Programs

Broad Intellectual Property Portfolio

mRNA Technology

mRNA for protein replacement

Self-amplifying mRNA (STARR™)

low-dose vaccine technology



LUNAR® Delivery

Hepatocytes – *intravenous*

Myocytes – *intramuscular*

Bronchial Cells – *inhaled*



Manufacturing Know-How

mRNA Drug Substance Production

mRNA Purification



LNP Drug Product Production

Fill Finish / Lyophilization








280+ Patents & Patent Applications

Pipeline of Arcturus-Owned mRNA Therapeutic Candidates

Franchise	Candidate	Funded By	Indication	Global Prevalence	Upcoming Milestone
Hepatic	LUNAR-OTC (ARCT-810)		Ornithine Transcarbamylase Deficiency	> 10,000	Phase 2 Interim Data H1 2024
Respiratory	LUNAR-CF (ARCT-032)		Cystic Fibrosis	85,000-100,000	Phase 1b Interim Data H1 2024

Each Arcturus-Owned Program Represents a Significant Commercial Opportunity

Pipeline of Partnered Self-amplifying mRNA Vaccines

Candidate	Partner	Indication	Stage
LUNAR-COV19 (ARCT-154) Monovalent: Ancestral		COVID-19	Approved (JP) MAA Filed (EU)
LUNAR-COV19 (ARCT-2301) Bivalent: Ancestral/Omicron BA.4/5		COVID-19	Phase 3
LUNAR-COV19 (ARCT-2303) Monovalent: XBB.1.5		COVID-19	Phase 3
LUNAR-FLU (ARCT-2138) Quadrivalent		Seasonal Influenza	Phase 1
LUNAR-FLU (Pandemic)		Pandemic Influenza	Pre-clinical

Greater than \$5 Billion in Potential Milestones and Profit Sharing / Royalties

CSL: Arcturus Therapeutics Global Vaccine Partner



- \$13.3 Billion USD Annual Revenue
- Operating in 40+ Countries Worldwide
- 32,000+ Employees Worldwide
- 13 Phase III programs – including ARCT-154
- Focused on four strategic technology platforms – plasma protein; recombinant technology; cell and gene therapy; and vaccines
- Therapeutic areas of focus of immunology, hematology, respiratory, cardiovascular and metabolic, transplant, nephrology and vaccines

CSL Seqirus

A World Leader in Flu Vaccines

- \$2.03 Billion USD Annual Revenue

CSL Seqirus is one of the Three Core Businesses of CSL

CSL Vaccine Partnership

Deal Value: Up to \$4.5 billion

- Collaboration combines CSL's global vaccine commercial and manufacturing infrastructure with Arcturus' expertise in mRNA design and modification, LUNAR[®] lipid nanoparticle (LNP) technology and manufacturing know-how.
- Deal terms encompass the development, manufacture, and commercialization of mRNA-based vaccines targeting COVID-19, Influenza and three additional respiratory infectious disease vaccines.

Terms of the Partnership

 CSLTM ARCTURUS[®]
therapeutics

\$200 million

Upfront Payment

\$1.3 billion

Development Milestones

\$3.0 billion

Commercial Milestones

40% profit sharing for COVID-19 vaccines

Up to **double digit royalties** for influenza and three additional respiratory infectious disease vaccines

Meiji: Background Information



Meiji Holdings Co., Ltd.

The Meiji Group provides food and pharmaceuticals indispensable to their customers

- \$7.9 Billion USD Net Sales (As of March 31, 2023)
- 113 Locations Worldwide with 17,290 Employees



Meiji Seika Pharma Co., Ltd.

Meiji Seika Pharma provides antibacterial drugs, vaccines, central nervous system drugs, and generic drugs

- \$1.4 Billion USD Net Sales (As of March 31, 2023)
- Received rights in Q4 2022 to conduct ARCT-154 clinical study in Japan
- Granted significant subsidy from Japanese government in Q4 2022
- Entered into agreement with CSL Seqirus in April 2023, responsible for obtaining regulatory approval, distribution, sales and marketing of ARCT-154 in Japan

Meiji Seika Pharma, a Subsidiary of Meiji Holdings Co. Ltd., Funded and Conducted the ARCT-154 Phase 3 Comparator Booster Study and Obtained Regulatory Approval in Japan

ARCALIS- Arcturus' Joint Venture mRNA Manufacturing Partner



ARCALIS is a CDMO Specializing in Manufacturing of mRNA Vaccines and Therapeutics

- Joint Venture Founded in 2021
- Ownership: Axcelead (51%) & Arcturus (49%), subject to dilution
- Meiji Seika Pharma is collaborating with ARCALIS for domestic mRNA vaccine production




ARCALIS' cGMP mRNA Drug Substance Manufacturing Plant

- Completed July 2023; Located in Minamisoma City, Japan
- Capacity: Up to 5 kg in bulk mRNA drug substance per year
- 78,059 sq ft (7,252 sq m) floor space

ARCALIS' cGMP mRNA Drug Product Manufacturing Expansion

- Capacity: 30 L (3 Lines); building to 100 L (2 Lines)



ARCALIS Awarded with \$165 Million in Grants from the Japanese Government

ARCT-154 Phase 3 Clinical Study Update

Phase 3 (Japan) Non-inferiority safety and immunogenicity trial


- Fully funded and conducted by Meiji Seiki Pharma
- ARCT-154 administered at an 83.3% lower dose than Comirnaty® (N = 828)
 - 50% of participants received ARCT-154 (5 mcg); 50% of participants received Comirnaty® (30 mcg)
- **Achieved Primary Endpoint** of non-inferiority of neutralizing antibody response against SARS-CoV-2 Ancestral strain compared to Comirnaty®
- **Achieved Secondary Endpoint** of superiority of ARCT-154 in neutralizing antibody response against SARS-CoV-2 Omicron BA.4/5 variant
 - Increased immunogenicity associated with ARCT-154 versus Comirnaty® at Day 29, with a geometric mean ratio of neutralizing antibodies against the vaccine strain of 1.43
- Generally safe and well tolerated
- **NDA submitted Apr 2023** to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for primary immunization
- **NDA submitted Jun 2023** to PMDA for booster use
- **European Medicines Agency (EMA)** has validated the marketing authorization application (MAA) for ARCT-154
- **Phase 3 Study published in *The Lancet Infectious Diseases***¹

ARCT-154 Received Approval from Japan's Ministry of Health, Labor and Welfare (MHLW)

¹Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, Yukihiro Yagi, Toru Kurosawa, Benjamin Greener, Ye Zhang, Judd L. Walson. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial, *The Lancet Infectious Diseases*, 2023, [https://doi.org/10.1016/S1473-3099\(23\)00650-3](https://doi.org/10.1016/S1473-3099(23)00650-3).

ARCT-154: More Durable Post-boost Immune Response

Preliminary Phase 3 Booster Trial Results Comparing ARCT-154 to Approved mRNA Vaccine



ARCT-154 Booster Shows Higher Durability of Immune Response Compared to Approved mRNA Vaccine

ARCT-810

Systemically Delivered mRNA for
Ornithine Transcarbamylase (OTC) Deficiency




LUNAR® - Lipid Nanoparticle (LNP) Delivery Technology


Proprietary, Biodegradable, Optimized for Each Cell Type



LUNAR® interacts with cell membrane




LUNAR® internalized inside endosome



mRNA release




mRNA translated into protein of interest



Ornithine Transcarbamylase (OTC) Deficiency

ARCT-810 Market Opportunity



The most common urea cycle disorder

The urea cycle converts neurotoxic ammonia to water-soluble urea that can be excreted in urine

Deficiency in OTC causes elevated blood ammonia, which can lead to neurological damage, coma, and death

10,000 worldwide prevalence




Unmet Medical Need

Present standard of care involves a strict diet (low protein, high fluid intake) plus ammonia scavengers (e.g. glycerol phenylbutyrate)

Present standard of care does not effectively prevent life-threatening spikes of ammonia

Severe OTC Deficiency patients are referred for liver transplant, currently the only cure



LUNAR-OTC Aims to Restore Enzyme Function


Establishing expression of OTC enzyme in liver has potential to restore urea cycle activity to detoxify ammonia, preventing neurological damage and potentially removing need for liver transplantation

LUNAR-OTC

Exceeds Target of 5% Enzyme Replacement in OTC-Deficient Mouse Model

- OTC deficiency impacts ureagenesis (ammonia detoxification)
- The main site of ureagenesis is the **periportal** region of the liver*
- The critical threshold of **5%** residual enzymatic OTC activity helps avoid severe manifestations of the disease (neonatal coma, mortality)*

Periportal Expression in the Liver of OTC Protein



LUNAR-OTC Treatment Increases OTC Expression in Mouse Periportal Hepatocytes (Main Site of Ureagenesis)

*Li, L. et al. PGC-1 α Promotes Ureagenesis in Mouse Periportal Hepatocytes through SIRT3 and SIRT5 in Response to Glucagon. Scientific Reports. 6:24156 | DOI: 10.1038/srep24156, April 2016

*Lamers, W.H., Hakvoort, T.B.M., and Köhler, E.S. 'Molecular Pathology of Liver Diseases' in Monga S.P.S. (ed.), MOLECULAR PATHOLOGY LIBRARY SERIES, Springer Publishing, New York, pp. 125-132 | DOI: 10.1007/978-1-4419-7107-4

*Scharre, Svenja. "In vitro enzyme activity predicts phenotypic severity in male individuals with ornithine transcarbamylase deficiency." SSIEM Annual Symposium 2022, Freiburg, Germany. 30 August – 2 September 2022. Poster Presentation.

ARCT-810 Clinical Update

Received FDA Fast Track Designation & Rare Pediatric Disease Designation in June 2023

Phase 1 (NZ) Study in Healthy Volunteers

- Completed dosing up to 0.4 mg/kg, total number of subjects N = 24, generally safe and well tolerated

Phase 1b (U.S.) Single Ascending Dose (SAD) Study in OTCD Adults

- Completed enrollment and dosing of all cohorts (N=16)
- Dose cohorts were 0.2, 0.3, 0.4 and 0.5 mg/kg; no serious or severe adverse events

Phase 2 (UK and EU) Single and Multiple Ascending Dose, Placebo-controlled Study in OTCD Adolescents & Adults

- Enrolling up to 24 subjects in two dose cohorts
- Up to 6 bi-weekly doses for each participant with the following endpoints
 - Primary Endpoints: Safety and tolerability
 - Secondary Endpoints: PK and PD (ureagenesis assay, plasma ammonia: 24-hr profile and peak level)
 - Exploratory Endpoints: Plasma amino acids and OTC enzyme activity; urine orotic acid

Interim Phase 2 Data Expected H1 2024

ARCT-032

Inhaled mRNA Therapeutic Candidate for
Cystic Fibrosis



Cystic Fibrosis

ARCT-032 Market Opportunity



Cystic Fibrosis

85,000-100,000 worldwide prevalence

Caused by mutations in the CFTR gene, resulting in poor chloride transport and dehydrated, sticky mucus in the airways


Chronic airway obstruction leads to infection and inflammation, which causes progressive airway damage and ultimately, respiratory failure



Unmet Medical Need

Highly effective CFTR modulators are not approved for treatment of all people with CF and may not be tolerated in others.

Standard of care therapies do not prevent the chronic, progressive loss of lung function that ultimately requires lung transplantation or leads to early death



LUNAR-CF Aims to Restore CFTR Function

An mRNA replacement therapy has the potential to produce wild-type CFTR into the lungs of CF patients, independent of genotype

Functional CFTR protein can restore chloride efflux in the airways, reducing mucus accumulation and airway damage and minimizing the progressive respiratory impairment observed in people with CF

ARCT-032 Clinical Update

Phase 1 Study in Healthy Volunteers (New Zealand)

- Objectives: Assess safety, tolerability and PK of ARCT-032 in healthy adults
- Completed dosing across 4 ascending single-dose cohorts (8 subject per cohort)
- Total number of subjects N = 32
- Safety and tolerability data supported transition to Phase 1b study

Phase 1b Study in Adults with Cystic Fibrosis (NZ) – Enrollment initiated October 2023

- Objectives: Assess safety, tolerability and PK of ARCT-032 in up to 8 adults with CF
- Status: First patient successfully completed two administrations of ARCT-032

The Cystic Fibrosis Foundation increased its financial commitment to ~\$25 Million to advance ARCT-032




ARCT-032 has received Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA

Phase 1b: Enrollment Initiated, Interim Data Expected H1 2024

LUNAR[®]-mRNA in Healthy Animals (four different species)

Successful delivery to airway epithelium; transduction demonstrated by Brown and Green staining




LUNAR[®] Delivery to Airway Epithelium is Demonstrated in Rodent and Non-Rodent Species

LUNAR®-mRNA in Cystic Fibrosis Ferret Model


Successfully Transduces Epithelium in the Presence of CF Mucus



Trachea



Bronchus




Green denotes functional expression of protein (Cre)

In collaboration with Univ. of Iowa; presented at North American CF Conference Nov 2023

LUNAR® Effectively Delivers mRNA Expressing Cre in a Ferret CF Model (G551D)

ARCT-032 in a Kalydeco®-responsive CF Ferret Model (G551D)

Proof of Activity: Mucociliary clearance improves after single administration of ARCT-032




- ARCT-032 (LUNAR®-CF)
- Kalydeco® (Positive Control)
- LUNAR-TdTomato (Negative Control)
- Off Kalydeco® (Baseline)

In collaboration with Univ. of Iowa; presented at North American CF Conference Nov 2023

ARCT-032 Functionally Restores Mucociliary Clearance to Normal Levels in CF Ferrets


ARCT-032 Restores CFTR Expression & Function

High Expression Levels of CFTR protein



In collaboration with UAB CFRC and Javier Campos-Gomez

Restored chloride activity (chloride gradient)



**P<0.01; Data from two F508del donors; Using chamber studies performed with chloride secretory gradient

In collaboration with Univ. of Alabama-Birmingham; presented at North American CF Conference Nov 2022

Restoration of CFTR Expression and Function in CF Human Bronchial Epithelial Cells

Arcturus Board of Directors



Peter Farrell, Ph.D.
Chairman of the Board



Edward W. Holmes, M.D.
Director of the Board



James Barlow, MA
Director of the Board



Magda Marquet, Ph.D.
Director of the Board



Jing L. Marantz, M.D., Ph.D.,
MBA
Director of the Board



Joseph E. Payne, MSc
Director of the Board
President & CEO



Andrew Sassine, MBA
Director of the Board, CFO



John Markels, Ph.D.
Director of the Board



